News Release

Trademark registration granted

Date: March 16, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. ("Wex" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued Certificates of Registration and granted Trademarks for our products, Tectin® and Tetrodin®.

Certified Trademark Registration has been reached after a successful application process with the U.S. authorities, and reflects the progress the Company is making towards commercialization of its new drugs.

Tectin® is designed for the analgesic market, specifically targeting inadequately controlled pain in patients with advanced cancer.

Tetrodin® is designed to provide a safe, cost effective primary withdrawal treatment solution for heroin and other opiate addiction to substances such as morphine, opium and methadone.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.